Ishara Investments LP Buys Shares of 70,000 Genmab A/S Sponsored ADR $GMAB

Ishara Investments LP bought a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 70,000 shares of the company’s stock, valued at approximately $2,156,000. Genmab A/S comprises about 2.5% of Ishara Investments LP’s investment portfolio, making the stock its 13th largest holding.

Other institutional investors have also recently added to or reduced their stakes in the company. Terra Nova Asset Management LLC bought a new stake in Genmab A/S during the fourth quarter valued at $1,866,000. Perpetual Ltd acquired a new position in shares of Genmab A/S during the fourth quarter valued at $25,478,000. Assetmark Inc. boosted its holdings in shares of Genmab A/S by 2,423.8% during the fourth quarter. Assetmark Inc. now owns 233,852 shares of the company’s stock valued at $7,203,000 after acquiring an additional 224,586 shares during the period. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Genmab A/S during the fourth quarter valued at $1,331,000. Finally, Oppenheimer Asset Management Inc. boosted its holdings in shares of Genmab A/S by 15.5% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 364,756 shares of the company’s stock valued at $11,234,000 after acquiring an additional 48,894 shares during the period. Institutional investors own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Truist Financial assumed coverage on shares of Genmab A/S in a report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target for the company. Guggenheim reduced their price target on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, February 23rd. BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Wolfe Research assumed coverage on shares of Genmab A/S in a report on Friday, March 27th. They set an “outperform” rating and a $32.00 price target for the company. Finally, Weiss Ratings downgraded shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.93.

Genmab A/S Stock Performance

GMAB stock opened at $25.39 on Thursday. The company has a market capitalization of $15.83 billion, a P/E ratio of 19.23, a PEG ratio of 1.47 and a beta of 0.85. The company has a 50-day simple moving average of $26.60 and a 200 day simple moving average of $29.08. Genmab A/S Sponsored ADR has a fifty-two week low of $20.23 and a fifty-two week high of $35.43. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.